Bifidobacterium longum spp. infantis

Eamonn Martin Quigley

doi:10.1016/B978-0-12-804024-9.00017-3

Bifidobacterium longum spp. infantis

Eamonn Martin Quigley

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Scopus citations

Abstract

Bifidobacterium longum spp. infantis 35624, originally isolated from the ileal mucosa of an individual free of gastrointestinal disease has been shown to survive transit through the gastrointestinal tract and to exert potent antiinflammatory effects in vivo in animal models. Other homeostatic effects, such as an enhancement of gut barrier function have also been demonstrated and of relevance to potential clinical indication, this organism has also been shown to accelerate intestinal transit and diminish visceral hypersensitivity. Not surprisingly, therefore clinical trials have focused on irritable bowel syndrome where consistent and clinically meaningful benefits have been demonstrated.

Original language	English (US)
Title of host publication	The Microbiota in Gastrointestinal Pathophysiology
Subtitle of host publication	Implications for Human Health, Prebiotics, Probiotics, and Dysbiosis
Publisher	Elsevier
Pages	143-144
Number of pages	2
ISBN (Electronic)	9780128040621
ISBN (Print)	9780128040249
DOIs	https://doi.org/10.1016/B978-0-12-804024-9.00017-3
State	Published - Jan 1 2017

Keywords

Antiinflammatory
Bifidobacterium longum spp. infantis 35624
Dendritic cells
Diverticulitis
Interleukin 10
Irritable bowel syndrome
Regulatory T-cell response
Visceral hypersensitivity

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/B978-0-12-804024-9.00017-3

Cite this

@inbook{5f60b74324e24934a5d27936af166d9d,

title = "Bifidobacterium longum spp. infantis",

abstract = "Bifidobacterium longum spp. infantis 35624, originally isolated from the ileal mucosa of an individual free of gastrointestinal disease has been shown to survive transit through the gastrointestinal tract and to exert potent antiinflammatory effects in vivo in animal models. Other homeostatic effects, such as an enhancement of gut barrier function have also been demonstrated and of relevance to potential clinical indication, this organism has also been shown to accelerate intestinal transit and diminish visceral hypersensitivity. Not surprisingly, therefore clinical trials have focused on irritable bowel syndrome where consistent and clinically meaningful benefits have been demonstrated.",

keywords = "Antiinflammatory, Bifidobacterium longum spp. infantis 35624, Dendritic cells, Diverticulitis, Interleukin 10, Irritable bowel syndrome, Regulatory T-cell response, Visceral hypersensitivity",

author = "Quigley, {Eamonn Martin}",

year = "2017",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-804024-9.00017-3",

language = "English (US)",

isbn = "9780128040249",

pages = "143--144",

booktitle = "The Microbiota in Gastrointestinal Pathophysiology",

publisher = "Elsevier",

address = "United States",

}

TY - CHAP

T1 - Bifidobacterium longum spp. infantis

AU - Quigley, Eamonn Martin

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Bifidobacterium longum spp. infantis 35624, originally isolated from the ileal mucosa of an individual free of gastrointestinal disease has been shown to survive transit through the gastrointestinal tract and to exert potent antiinflammatory effects in vivo in animal models. Other homeostatic effects, such as an enhancement of gut barrier function have also been demonstrated and of relevance to potential clinical indication, this organism has also been shown to accelerate intestinal transit and diminish visceral hypersensitivity. Not surprisingly, therefore clinical trials have focused on irritable bowel syndrome where consistent and clinically meaningful benefits have been demonstrated.

AB - Bifidobacterium longum spp. infantis 35624, originally isolated from the ileal mucosa of an individual free of gastrointestinal disease has been shown to survive transit through the gastrointestinal tract and to exert potent antiinflammatory effects in vivo in animal models. Other homeostatic effects, such as an enhancement of gut barrier function have also been demonstrated and of relevance to potential clinical indication, this organism has also been shown to accelerate intestinal transit and diminish visceral hypersensitivity. Not surprisingly, therefore clinical trials have focused on irritable bowel syndrome where consistent and clinically meaningful benefits have been demonstrated.

KW - Antiinflammatory

KW - Bifidobacterium longum spp. infantis 35624

KW - Dendritic cells

KW - Diverticulitis

KW - Interleukin 10

KW - Irritable bowel syndrome

KW - Regulatory T-cell response

KW - Visceral hypersensitivity

UR - http://www.scopus.com/inward/record.url?scp=85027353934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027353934&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-804024-9.00017-3

DO - 10.1016/B978-0-12-804024-9.00017-3

M3 - Chapter

SN - 9780128040249

SP - 143

EP - 144

BT - The Microbiota in Gastrointestinal Pathophysiology

PB - Elsevier

ER -

Bifidobacterium longum spp. infantis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this